Patent applications published 20 October 2010

Published: 17-Nov-2010
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Ketone bodies and ketone body esters as blood lipid lowering agents
    Isis Innovation 2240017*

  • Methods for measuring a patient response upon administration of a drug and compsns thereof
    SRC 2240018*

  • Acid mimic compounds for the inhibition of isoprenyl-S-cysteinyl methyl transferase
    Signum Biosciences 2240019*

  • Intrathecal treatment of neuropathic pain with A2AR agonists
    Pgx Health 2240020*

  • Novel SEH inhibitors and their use
    GlaxoSmithKline 2240021*

  • Pharmaceutical compsns
    Charleston Laboratories 2240022*

  • Antiviral drugs for treatment of arenavirus infection
    Siga Technologies 2240023*

  • Compounds for the treatment of metabolic disorders
    Wellstat Therapeutics 2240024*

  • Novel sEH inhibitors and their use
    GlaxoSmithKline 2240025*

  • Novel sEH inhibitors and their use
    GlaxoSmithKline 2240026*

  • Organic compounds
    Intra-Cellular Therapies 2240028*

  • Compounds for inflammation and immune-related uses
    Synta Pharmaceuticals 2240029*

  • Novel Bacillus thuringiensis gene with coleopteran activity
    Pioneer Hi-Breed International 2240030*

  • Devices, formulations and methods for delivery of multiple beneficial agents
    Intarcia Therapeutics 2240155*

  • Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
    BioInvent International 2240156*

  • Ophthalmic preparations
    Novavax 2240157*

  • Stabilised injectable formulation of pregabalin
    Intas Pharmaceuticals 2240158*

  • Alendronate formulations, method of making and method of use thereof
    Actavis Group 2240159*

  • Lubricant mousse
    LRC Products 2240160*

  • Enhanced delivery of antifungal agents
    Keller, Brian; Wu, Niam 2240161*

  • Nanoparticles comprising a non-ionisable polymer and an amine-functionalised methacrylate copolymer
    Bend Research; Bloom, Corey; Crew, Marshall; Miller, Warren 2240162*

  • Pharmaceutical compsns of amlodipine and valsartan
    Lupin 2240163*

  • Pharmaceutical compsn
    Novartis 2240164*

  • Soluble hydrophobic core carrier compsns for delivery of therapeutic agents, methods of making and using the same
    PharmaIN 2240165*

  • Mesalazine tablet
    Disphar International 2240166*

  • Extruded rod-shaped devices for controlled release of biological substances to humans and animals
    Ludwig-Maximilians-Universität 2240167*

  • Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
    The Johns Hopkins University 2240168*

  • Cytostatic compsn
    Tishkin, Sergey; Laskavyj, Vladislav 2240169*

  • Methods and compsns for treatment for coronary and arterial aneurysmal subarachnoid haemorrhage
    Vanderbilt University 2240170*

  • Inhibitors of carbonic anhydrase IX
    Molecular Insight Pharmaceuticals 2240171*

  • Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukaemia
    Novartis 2240172*

  • Delayed release pharmaceutical compsn of duloxetine
    Alphapharm 2240173*

  • Pharmaceutical compsns comprising N-[2-diethylamino)-ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden-)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxamide
    Ratiopharm 2240174*

  • Compounds with MDR1-inverse activity
    The Government of the United States of America as represented by the Department of Health and Human Services 2240175*

  • Compsns and methods for enhancing the activity of podophyllotoxin
    Do-Coop Technologies 2240176*

  • Treatments for neuropathy
    Children’s Medical Centre Corp 2240177*

  • Prolyl hydroxylase inhibitors
    GlaxoSmithKline 2240178*

  • Imidazopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
    Sanofi-Aventis 2240179*

  • Prevention of recurrence of urethral stricture after and conventional treatment
    Windgan Trading 2240180*

  • Combined use of 25-hydroxy-vitamin D3 and vitamin D3 for improving bone mineral density and for treating osteoporosis
    DSM IP Assets 2240181*

  • Treating hyperglycaemia with 25-hydroxyvitamin D3
    DSM IP Assets 2240182*

  • Combination of vitamin D and 25-hydroxyvitamin D3
    DSM IP Assets 2240183*

  • Compsns and methods for influencing recovery from strenuous physical activity
    Nestec 2240185*

  • A compsn comprising bifido-bacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
    NV Nutricia 2240186*

  • Absorbent ingestible agents and associated methods of manufacture and use
    Wellosophy Corp 2240187*

  • Ointment of the basis of a dialysate of calves’ blood
    Badrawi, Mohamed 2240188*

  • Microvesicles
    Lydac Neuroscience 2240189*

  • Nutraceutical compsn and methods of use
    Dacy Tech 2240190*

  • Compsn comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases
    Yang Ji Chemical 2240191*

  • Treatment for dermatological conditions
    Armstrong, Robert 2240192*

  • Compsn comprising the extracts of Lindera obtusiloba for prevention and treatment of cardiovascular agents
    Yang Ji Chemical; Han Wha Pharma 2240193*

  • Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
    Sciclone Pharmaceuticals 2240194*

  • Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
    Sciclone Pharmaceuticals 2240195*

  • Clusterin-derived peptide
    Compugen 2240196*

  • Use of a homeoprotein of the bicoid family for preventing or treating retinal ganglionic nerone degeneration
    Centre National de la Recherche Scientifique; Ecole Normale Supérieure 2240197*

  • Compsn for absorption through mucous tissue
    Hernuss, Peter 2240198*

  • Influenza B vaccines
    Sanofi Pasteur Biologics 2240199*

  • Therapeutic myelin sheath derived antagonist peptide conjugates
    Eldrug; Matsoukas, John; Tselios, Theodore 2240200*

  • Recombinant rift valley fever (RVF) viruses and methods of use
    The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 2240201*

  • Allergy vaccine compsn for mucosal administration
    ALK-Abelló 2240202*

  • Alpha 5-beta 1 antibodies and their uses
    Bristol-Myers Squibb; Pfizer 2240203*

  • Anti-CLTA-4 antibodies with reduced blocking of binding of CTLA04 to B7 and uses thereof
    Mederax 2240204*

  • N-alkoxyamide conjugates as imaging agents
    Lantheus Medical Imaging 2240206*

  • Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethy;-2-methyl-propyl)-phenol
    Grünenthal 2240431*

  • Process for the preparation of isoimenol
    Mallinckrodt 2240432*

  • Polymeric forms of oseltamivir phosphate
    F Hoffmann-La Roche 2240433*

  • 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders
    Ligand Pharmaceuticals 2240434*

  • Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant E6020
    Eisai R&D Management 2240435*

  • Novel process for the preparation of vorinostat
    Generics (UK) 2240436*

  • Process for producing 2-hydroxy-4-methylthiobutaneamide
    Sumitomo Chemical 2240437*

  • 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogues
    Wisconsin Alumni Research Foundation 2240438*

  • (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogues
    Wisconsin Alumni Research Foundation 2240439*

  • 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogues
    Wisconsin Alumni Research Foundation 2240440*

  • Process for the preparation of 6-substituted-1-(2H)-isoquinolinones
    Sanofi-Aventis 2240441*

  • Preparation useful in synthesis of atorvastatin
    Medichem Korea 2240442*

  • Proline analogues as ligands for cannabinoid receptors for the treatment of pain
    Purdue Pharma 2240443*

  • Compounds having CRTH2 antagonist activity
    Oxagen 2240444*

  • Novel salt of tegaserod
    Generics (UK); Mylan Development Centre Private 2240445*

  • Morpholine derivatives as antiobesity agents
    AstraZeneca 2240447*

  • Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Vitae Pharmaceuticals 2240448*

  • Novel anti-infectious derivatives, method for the production thereof, pharmaceutical compsns containing same and uses of said derivatives in treatment
    Centre National de la Recherche Scientifique - CNRS; Université Paul Sabatier de Toulouse III 2240449*

  • TRPA1 antagonists
    Abbott Laboratories 2240450*

  • Certain chemical entities, compsns and methods
    Intellikine 2240451*

  • Certain chemical entities, compsns and methods
    Intellikine 2240452*

  • Substituted-aryl-2-phenylethyl-1H-imidazole compounds as sub-type selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
    Allergan 2240453*

  • Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
    Array Biopharma; Genentech 2240454*

  • Method for the production of 3,6-dihydro-L 3,5-triazine derivatives from metformin and paraldehyde derivatives
    Poxel SAS 2240456*

  • Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
    Bayer Schering Pharma AG 2240457*

  • Aryl sulphonamides as effective analgesics
    Boehringer Ingelheim International 2240458*

  • Epoxidised soyate diesters and methods of using the same
    Polyone 2240459*

  • Branched diepoxide compounds for the treatment of inflammatory disorders
    Emory University 2240460*

  • Substituted furans and use thereof
    Bayer Schering Pharma AG 2240461*

  • Therapeutic compounds
    Allergan 2240462*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now